Form 4: Apellis Officer Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Business & Strategic Officer, Mark DeLong, sold 1,334 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Mark DeLong, Chief Business & Strategic Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction involving the company's common stock.
• On January 20, 2026, DeLong sold 1,334 shares of Apellis common stock at a price of $19.7929 per share.
• The sale was executed to cover tax withholding obligations associated with Restricted Stock Units (RSUs) that vested on January 16, 2026.
• Following this transaction, DeLong directly beneficially owns 81,724 shares of Apellis common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax withholding obligations on vested Restricted Stock Units, indicating a neutral sentiment regarding company performance or insider confidence.

Positives

• Vesting of Restricted Stock Units (RSUs) for Mark DeLong, indicating compensation and retention for a key executive.

Negatives

• A reduction in direct beneficial ownership by 1,334 shares by a key executive.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but given its routine nature for tax purposes, it is unlikely to significantly impact shareholder sentiment or the company's valuation.
• Employees: The vesting of Restricted Stock Units and subsequent tax-related sale are standard components of executive compensation, reflecting the company's incentive and retention programs.

Key Dates

Recommendation

The Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax withholding on vested Restricted Stock Units. This type of transaction is common and does not typically signal a change in management's outlook or the company's fundamentals, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, insider transaction, Form 4, stock sale, RSU, restricted stock units, tax withholding, executive compensation